Article Information
History
- February 24, 2024.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- 1Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York
- 2Severn Health Solutions, Severna Park, Maryland
- ↵*correspondence to Dr. Steven Lehrer, Box 1236 Radiation Oncology, Mount Sinai Medical Center, 1 Gustave L. Levy Place, New York 10029 or steven.lehrer{at}mssm.edu
Competing interests: The authors declare no competing interests. Dr. Lehrer and Dr. Rheinstein contributed equally to the conception, writing, and data analysis of this study.
Posted February 24, 2024.
Salbutamol, a short acting beta-2 agonist, reduces risk and improves prognosis of prostate cancer
